Despite advances in the treatment of human immunodeficiency virus (HIV) [1] , the central nervous system (CNS) is still often affected by this disease. Impairment of cognition caused by HIV disease is known as HIV-associated neurocognitive disorder (HAND) [2] . Importantly, compared with unaffected populations, HAND, even in its mild form, is associated with lower medication adherence [3] , less ability to perform the most complex daily tasks [4] [5] [6] [7] , worse quality of life [8] , difficulty obtaining employment, and shorter survival [8] . Athough the incidence of the most severe form of HAND-HIV-associated dementia (HAD)-has declined in the era of combination antiretroviral therapy (cART) [9] , the incidence and prevalence of milder forms (asymptomatic neurocognitive impairment [ANI] and mild neurocognitive disorder [MND] ) have remained stable or perhaps even increased [10] . In addition, as cART-treated patients survive into older age, there could be a rise in HAND due to interactive effects of chronic immune activation and aging on the CNS [11] .
Gaps remain in translating emerging neuro-HIV research findings into clinical practice [12] . To address this problem, the Mind Exchange program was established with the goal to provide guidance of direct relevance to daily clinical practice. In this communication we describe the process of expert consensus development and specific recommendations on HAND diagnosis and management, based on the best available evidence.
METHODS
Sixty-six specialists from a range of disciplines (including HIV clinicians, neurologists, neuropsychologists, clinical psychologists, and psychiatrists who care for and have experience with HIV patients) from 30 countries provided input into the Mind Exchange program, which took place between February 2011 and January 2012. The program was overseen by a steering committee of 5 experts, including 2 infectious disease specialists (from Italy and the United States), a neurologist (from Germany), a neuropsychiatrist (from the United States), and a clinical psychologist (from Spain).
The program comprised several stages ( Figure 1) . A broad list of clinical questions across the 5 topics (screening, diagnosis, monitoring, treatment/interventions, and prevention of HAND) was generated by a core group of international experts in a face-to-face meeting. A total of 83 questions were identified and included in a questionnaire for prioritization by the core expert group and a wider group of HIV clinicians; the questionnaire was circulated and returned by email, with 65 individuals from 30 countries responding. This process resulted in a final set of 14 questions identified as of critical clinical importance to be addressed during the remainder of the program.
A comprehensive literature search of PubMed and the Cochrane Library was performed for each of the 14 questions by a research or clinical fellow, or a member of the core expert group, using question-specific search strings and predefined limits (no time limit was specified). Abstracts from key international conferences were also searched.
For each question, a draft practical answer was generated by 2 or 3 members of the core expert group based on the findings of the literature review and their clinical opinion. Answers were reviewed by the steering committee and refined by the expert group. Following this, an international meeting with the steering committee, core expert group, and broader HIV clinician group was held to discuss and further refine the draft answers. These 63 participants from 30 countries voted on their level of agreement with each draft answer using a scale of 1-9 (where 1 = strong disagreement and 9 = strong agreement). Consensus was defined as at least 75% of participants scoring within the 7-9 range. If <75% of participants scored within this range, the answer was debated and revised, followed by a second vote. Similar voting methodology has been employed in development of other consensus-based guidelines in the United Kingdom [13, 14] .
The core expert group then further refined the answers to improve clarity and to reduce their length for this document. No substantive changes in the content or meaning of the answers were made. A level of evidence and grade of recommendation was assigned to each statement in the final answers, in accordance with the Oxford Centre for EvidenceBased Medicine (CEBM) 2009 criteria [15] . This system covers all study types and is appropriate for assigning levels of evidence across the broad range of clinical questions.
RESULTS
The 14 key questions are presented in Table 1 . Agreement was achieved on the draft answers to all 14 questions at the international meeting. Here we present a summary of the major points of the guidance derived from each of the answers to the 14 questions.
Screening for HAND
It is appropriate to assess neurocognitive functioning in all patients with HIV (CEBM 5; grade of recommendation [GOR] D) as there is limited rationale for screening only symptomatic patients (CEBM 2b) [16] [17] [18] [19] or only those with recognized risk factors for HAND (eg, nadir CD4 + T-cell counts <200 cells/μL) (CEBM 2b; GOR C) [20] . Furthermore, because the CNS is commonly one of the first targets of HIV infection, good practice suggests that a patient's neurocognitive profile should be assessed early (within 6 months of diagnosis, as soon as clinically appropriate) using a sensitive screening tool (CEBM 5; GOR D) [21] . If possible, screening should take place before the initiation of cART (CEBM 5; GOR D), as this will establish accurate baseline data and allow for subsequent changes to be more accurately assessed. Although there are insufficient data to establish the best time for follow-up assessments (CEBM 2b) [22] , the consensus group agreed that screening for HAND should occur every 6-12 months in higher-risk patients or every 12-24 months in lower-risk patients (CEBM 5; GOR D). Several risk factors (Table 2 ) have been independently associated with an increased likelihood of HAND. The clinical significance of risk factors should be considered in light of the patient's full medical history. Screening should also be carried out immediately if there is evidence of clinical deterioration (CEBM 5, GOR D) or at the time of major changes in clinical status (eg, cART initiation or change or diagnosis of mental health disorders; CEBM 3b; GOR C) [23] .
Many brief screening approaches have been proposed for the detection of neurocognitive disorders; the benefits and limitations of those tools for which there is substantial literature on their use in HAND are presented in Table 3 . In addition to paper-based tools, some computerized tools are also available for screening (eg, CogState [34] ; CANTAB reaction time [35] ). No single tool is suitable for use across all practice settings, and the choice of a HAND screening tool depends on a number of considerations, including the availability of a clinician suitably trained to administer and interpret each tool; whether the clinician wants to screen for HAD only or for the milder forms of HAND; the financial and time cost of testing; and the characteristics of the population in which the tool will be used (CEBM 5; GOR D). Neurocognitive screening tools • Very fast to administer (3-5 min)
• Very fast to score and interpret • Excellent specificity [2] using standard and validated instruments for detection of HAND administered and interpreted by appropriately trained professionals [37] . Furthermore, tests should be performed at times when the patient is not experiencing excessive fatigue or severely depressed mood, and when the general medical status is stable (ie, without other active systemic diseases). The NP tests selected for use should ideally have been validated in the language and culture of the patient. The use of appropriate normative data from a healthy community population is recommended for the correct interpretation of standard NP tests with quantitative outcomes [37] [38] [39] . Furthermore, in follow-up testing, the use of normative longitudinal data is recommended to adjust for the impact of repeated testing (the "learning or practice effect") on test sensitivity (CEBM 1c; GOR B) [40, 41] .
Differential Diagnosis of HAND
Various conditions (comorbidities) may either suggest a non-HIV cause for NCI, or their presence may compound HIV's effect on the CNS. To identify comorbidities and make a judgment as to whether or not they contribute to NCI, a number of assessments (in addition to neurocognitive assessments already described) should be used in HIV-infected individuals with suspected or demonstrated NCI (Table 4 ). In addition, in older patients, it is important to differentiate HAND from neurodegenerative disorders. Here both pattern and course of progression of NP impairment, and in certain instances, ancillary diagnostic information such as brain imaging, cerebrospinal fluid (CSF) studies, and blood tests can be helpful (Table 4) . For example, in the older person with well-controlled HIV, the differential diagnosis of Alzheimer's disease may be suggested by progressive cognitive impairment with prominent difficulties in learning new information, rapid forgetting, and language problems (eg, deficits in naming and comprehension, which are not prominent in HAND), in the context of apolipoprotein e4 polymorphism (CEBM 2b; GOR B) [56] [57] [58] [59] .
CSF analysis should be performed in patients with neurological symptoms or signs (CEBM 2a; GOR B), preferably at presentation (CEBM 2a; GOR C) [46, 47] , and should be preceded by imaging (to avoid lumbar puncture-associated risk). In these patients, CSF analysis should be performed to exclude non-HIV neurological conditions (eg, CNS-opportunistic infections and other infections; CEBM 2b; GOR C) [46] [47] [48] [49] 60] .
Monitoring HAND
In the absence of data from large-scale outcome studies of HAND (CEBM 5; GOR D), experts recommend that the frequency of neurocognitive monitoring should be increased in patients who (1) demonstrate clinical worsening of HIV disease; (2) have a history of low nadir CD4 (eg, <200 cells/ μL), which is associated with worse neurocognitive outcomes; (3) are not receiving ART; (4) do not achieve virologic suppression despite cART; and (5) develop new or worsened neurologic symptoms or signs (CEBM 5; GOR D). Clinically stable patients can be reviewed less often (approximately every 2 years). Patients may detect neurocognitive difficulties before they are noted by clinicians. Consequently, those reporting neurocognitive difficulties should be evaluated fully (CEBM 1b; GOR B) [24] . However, self-report alone can either underestimate (as a result of impaired patient insight) or overestimate (as a result of comorbid anxiety and depression) true neurocognitive difficulties (CEBM 1b) [61] . Therefore, the consideration of both the clinical history and the personal complaints is needed to best determine time to follow-up. Recommendations for monitoring patients are presented in Table 5 . For patients commencing cART, the earliest time point at which improvement is expected is 1 month, with several studies showing improvement by 2 months [67, 68] , and some by as much as 9 months (CEBM 1b) [64, 69] . Earlier responses may be seen in patients who are naive to cART (CEBM 1a and 1b) [68, 70, 71] .
Most patients who attain virologic suppression in blood will also do so in CSF. Thus, there is no general indication to repeat CSF analysis following cART initiation (CEBM 2b; GOR B) [60] . CSF analysis may be repeated after at least 12 weeks in patients with undetectable plasma HIV RNA who do Will help to establish the premorbid level of neurocognitive functioning (CEBM 3b; GOR C) [42] Assessment of past and active alcohol and substance abuse or dependence using DSM-IV Acute intoxication or withdrawal or active substance abuse or dependence can interfere with reliable evaluation of neurocognitive status (CEBM 3a; GOR B) [43] [44] [45] . Poor performance on NP testing may be explained, at least in part, by extensive past history of alcohol or substances Assessment of depression, anxiety, and posttraumatic stress disorder using a structured questionnaire (CEBM 5; GOR D)
To identify psychiatric conditions that may influence self-reported neurocognitive performance as well as performance on some neurocognitive tests not improve neurologically (CEBM 5; GOR D), and in those who changed cART because of CSF viral escape (CEBM 4; GOR C) [72] .
Treatment and Prevention
There are no systematic published studies on the progression of ANI to MND, or of MND to HAD. There is some evidence that markers of progression of HIV disease (low CD4 + T-cell count, AIDS diagnosis, high plasma HIV RNA), NP status (worse processing speed), and major depressive disorder may be associated with worsening of NP performance over time. It is not possible from existing data to conclude whether patients with successful treatment (ie, plasma HIV RNA <50 copies/ mL) are at risk of progression and there are no systematic studies addressing the extent to which neurocognitive deficit may be permanent or reversible. Data show that cART for approximately 1 year is associated with modest benefits in NP functioning, particularly attention, processing speed, and executive performance (CEBM 1a) [73] [74] [75] [76] [77] . The degree of improvement correlates with changes in CD4 + T-cell counts (CEBM 1a) [42, [78] [79] [80] [81] [82] . Treatment with antiretrovirals that have greater distribution into the CNS Patients with HAND not on cART • Periodically reassessed, perhaps as frequently as monthly if practical (CEBM 3b; GOR C) [62, 63] Patients with HAD or MND commencing cART • Monitored clinically, initially at months 3 and 6, then semiannually until a plateau of response has been observed (CEBM 1b; GOR B) [64, 65] , and annually thereafter • If there is no clinical response or if there is deterioration at early time points, other causes of impairment should be considered (CEBM 5; GOR D) • There may be a bidirectional relationship between cognition and cART medication adherence, with poor adherence being associated with poor virologic response; therefore, specific interventions to optimize cART adherence should be employed [110] Patients with ANI commencing therapy
• Monitored initially at 6 months and annually thereafter (CEBM 1b; GOR B) [65, 66] Abbreviations: ANI, asymptomatic neurocognitive impairment; cART, combination antiretroviral therapy; CEBM, Centre for Evidence-Based Medicine; GOR, grade of recommendation; HAD, HIV-associated dementia; HAND, HIV-associated neurocognitive disorder; HIV, human immunodeficiency virus; MND, mild neurocognitive disorder. 
Integrase inhibitors Raltegravir
Abbreviations: CNS, central nervous system; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Source: Letendre et al [83, 84] .
(CNS penetration) has been associated with better neurocognitive outcomes in some trials (CEBM 2b; GOR B); however, results are not consistent and randomized trials with large sample sizes are needed to corroborate these findings (Table 6 ) [64, 74, 76, 85] . Thus, the benefits of changing cART to improve CNS penetration for individuals whose infection is already well controlled are unproven. In patients with persistent or worsening NCI and CSF HIV RNA <50 copies/mL, other possible causes of NCI must be considered (CEMB 5; GOR D). After ruling out alternative diagnoses, HAND should be considered. If HIV RNA is detectable in the plasma, we suggest first obtaining confirmation that the patient is adherent to their cART, as neurocognitive difficulties can interfere with adherence and, second, adapting the regimen according to resistance profiles and possibly the CNS penetration-effectiveness (CPE) score if appropriate (CEBM 2b; GOR C) [86] . If HIV RNA is undetectable in the plasma and CSF, we recommend that a more sensitive HIV RNA assay with a lower limit of detection of 1-2.5 copies/mL be performed on the CSF (currently available only in research settings). If HIV RNA is detectable using a more sensitive assay, modification of the cART regimen according to CPE score (when appropriate) and to CSF viral resistance profile (if possible) may be an option. If the more sensitive HIV RNA assay is not available, the clinician may suspect the possibility of low-level CSF HIV RNA >2.5 copies/mL and consider regimen modification (CEBM 2b; GOR C) (Figure 2 ) [87, 88] .
If treated patients have persistent NCI despite effective cART, the possibility of cART neurotoxicity must be considered. Evidence in the literature for antiretroviral neurotoxicity causing persistent NCI during stable cART is limited because it has not been systematically studied. Although some findings suggest neurocognitive improvement following cessation of cART (CEBM 3b) [89, 90] , other reports question that evidence [91] . The use of treatment interruption is not recommended since its benefits do not outweigh its risks (CEBM 1b; GOR B) [92] [93] [94] . Evidence for the development of neuropsychiatric symptoms (eg, sleep disturbance, dizziness, anxiety, depression) is greatest for efavirenz; however, these effects typically occur early in therapy and in many cases resolve spontaneously [95, 96] . If cART neurotoxicity is suspected, and CNS side effects persist for >4 weeks, consider therapeutic drug monitoring followed by dose adjustment if indicated (CEBM 2b; GOR C) [97, 98] . If symptoms continue to persist, consider switching to an alternative treatment (CEBM 5; GOR D) [99] .
In addition to cART, several drugs (including minocycline, memantine, selegiline, lithium, valproic acid, lexipafant, CPI 1189, peptide T, nimodipine, and psychostimulants) have been evaluated as potential therapies for HAND. Although there is evidence of good safety and tolerability in most studies, effectiveness has not been established (CEBM 1a) [100] . No therapy other than cART is currently recommended for routine treatment of HAND in the clinic.
Direct and indirect data tend to show benefits in treating potential comorbidities, such as hepatitis C virus, cardiovascular risk factors, metabolic disorders, major depressive disorder, and anxiety disorders, to reduce the severity of NCI in HIV-infected patients (CEBM 2b; and 5; GOR C) [101, 102] .
There is a limited evidence base for the earlier introduction of cART for the prevention of HAND (CEBM 2b; GOR B) [103] . In general, current treatment guidelines should be followed (CEBM 2b; GOR C) [103] . Earlier treatment of patients at high risk of NCI, for instance, older people, could be considered (CEBM 5; GOR D). There are no data on the use of CNS-penetrating cART for preventing (as opposed to treating) HAND; therefore, there is no evidence to support the initiation of therapy with better CNS-penetrating regimens in neurologically normal patients, or in those at greater risk of HAND (CEBM 5; GOR D).
DISCUSSION
We have summarized the key points of the Mind Exchange program, a consensus-based, evidence-driven process to develop and consolidate practical guidance for the screening, diagnosis, monitoring, treatment, and prevention of HAND. The Mind Exchange program included an academically rigorous process, supported by a large number of leading HIV physicians, representing a broad range of clinical opinion from diverse geographic regions and a variety of clinical practices, with the intent to provide insightful, up-to-date, and evidence-based guidance to the HIV medical community. The program was designed to complement rather than duplicate existing guidance in HIV treatment guidelines.
This program does have several limitations. First, although literature searches were based on carefully constructed, formalized keyword strings, the review of the literature does not meet strict criteria for a systematic review. Nonetheless, the searches were thorough, well documented, and carried out in 2 databases and relevant HIV congresses, thus providing a broad database with which to address each of the 14 questions. Second, to provide the most clinically useful guidance within a manageable timeframe, the program did not set out to address all aspects of HAND management, but rather addressed the questions prioritized as most important to clinical practice. Despite this restriction, the answers provided do give a good spread of guidance across the range of HAND management. Finally, the guidance does not take into account differing resource settings, and it may not be possible for all physicians to apply all aspects of the guidance within their practice.
The consensus process has also highlighted areas of HAND diagnosis and management where further research and guidance is needed. For example, although good practice suggests that all patients with HIV should be screened for HAND as early as possible in their disease using a sensitive screening tool, some of the most widely available screening tools have limitations, particularly in their ability to detect milder forms of NCI. Other testing requires involvement of a specialist, especially for scoring and interpretation. In brief, there is no standard and validated, easy-to-perform test to screen for minor neurocognitive disorders applicable in all HIV-infected patients. The HIV Dementia Scale with a modified cutoff of 14 points (as opposed to the classical cutoff of 10 points) is useful in identifying those persons with HAD, but this scale and others are still limited in their ability to detect (and differentiate from other diagnoses) ANI and MND.
There are no data on the role of preventive measures for HAND and there are only emerging data on the progression of milder forms of impairment and the clinical significance of asymptomatic impairment. There are no data regarding the appropriate short monitoring tools for reviewing neurocognitive performance in patients who have been diagnosed with HAND; while access to full NP assessment is appropriate in some patient groups, it remains an option that is not widely affordable. Short and validated monitoring tools for HAND are urgently needed. Last, data from large randomized trials are needed to confirm the potential association of the CNS penetration of cART with improved neurocognitive performance, while issues of potential long-term neurotoxicity demand investigation.
The clinical importance of HAND is receiving increasing attention as patients are surviving longer and neurocognitive health has become an issue of importance in the HIV and general community. Both HIV and non-HIV forms of NCI are diagnosed much earlier than they were in the past [104] . Despite this, some have questioned the benefit of early diagnoses when there is no proven treatment. But in the context of HIV infection, which is likely to be a chronic disease lasting decades in most patients, we have highlighted that there are already better treatment practices and that early diagnosis is a crucial step in identifying patients at risk, as well as patients in need of more frequent monitoring or specific interventions, including medication adherence checks.
Our program has attempted to address the fact that among many HIV clinicians, the knowledge of practical procedures to deal with HAND is limited. This highlights the need for further education and training on the importance of HAND and its clinical implications, particularly around raising awareness of the link between HAND and cART nonadherence, improving understanding of ANI, increasing the understanding and implementation of the neurocognitive diagnosis of HAND, and initiating effective management of HAND once it has been identified.
In conclusion, the Mind Exchange program complements existing guidelines, providing practical guidance in the diagnosis, ongoing monitoring, and treatment of HAND, which is of direct relevance to daily practice.
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